Skip to content

Ketamine for Adolescent Depression

February 28, 2023 DOI: 10.64239/pi-capst0804 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Double-blind
Population Adolescents with severe major depression
Intervention Ketamine
Duration 24 hours after infusion
Topics Depression Esketamine Ketamine
Key findings Ketamine had a strong effect size for reducing depressive symptoms 24 hours after infusion in adolescents with severe major depression.

Abstract

Ketamine therapies can offer rapid relief of depression and an antisuicidal effect, making them of particular interest for adolescents with treatment-resistant depression. In 1 randomized, double-blind study of adolescents with severe major depression, ketamine had a strong effect size for reducing depressive symptoms 24 hours after infusion. Currently, there is minimal investigation and few studies on the use of ketamine in treatment-resistant adolescents with depression.

Comparable studies

Other randomized controlled trials on ketamine for depression, most cited first.

Study Year Design Participants
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial Patients with treatment-resistant major depression experiencing a major depressive episode 2013 Randomized controlled trial n = 73
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Adults with moderate to severe nonpsychotic depression and a history of nonresponse to... 2019 Phase 3, double-blind, active-controlled, multicenter randomized controlled trial n = 227
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression Adults with treatment-resistant depression who achieved stable remission or stable... 2019 Phase 3, multicenter, double-blind, randomized withdrawal study n = 297
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression Adults with DSM-IV-TR diagnosis of major depressive disorder and history of inadequate... 2017 Phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study n = 67
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Depressed patients at imminent risk for suicide 2018 Randomized controlled trial n = 68

Related reading

Explore topics

Depression Esketamine Ketamine

By condition and practice

Ketamine for depression